恒瑞医药：子公司收到SHR-1139注射液临床试验批准通知书

Core Viewpoint - Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-1139 injection, a self-developed therapeutic biological product aimed at treating ulcerative colitis, with no similar drugs approved in the market currently [1] Group 1 - The approval notification for SHR-1139 injection was issued by the National Medical Products Administration [1] - The clinical trials are expected to commence shortly [1] - SHR-1139 injection is designed to enhance treatment by inhibiting inflammatory responses and maintaining epithelial barrier mechanisms [1]